30-day average of 9 articles ยท scale โ100 to +100
Across 9 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Colgate-Palmolive Company news is Somewhat Bullish (+44)
on a scale from โ100 to +100.
That is up 18 points from the previous 30 days (+26).
๐ India revenue rose 12.2% YoY to INR 1,705.7 crore in Q3 2026.
โ ๏ธ EBITDA margin fell to 28% as brand spending outpaced earnings growth.
Bullish +65
Colgate-Palmolive India stock set for INR 24 interim dividend
AI-generated analysis
Key insights
๐ Colgate-Palmolive India reported a 12.2% year-over-year increase in revenue from operations, reaching INR 1,705.7 crore for the quarter ended September 30, 2026.
๐ฐ Net profit grew 4.2% to INR 342 crore, demonstrating resilient profitability despite macroeconomic headwinds in the Indian consumer market.
๐ฆท The toothpaste portfolio achieved high-single-digit volume growth, bolstered by the premium range and the launch of Colgate MaxFresh.
โ ๏ธ EBITDA margin declined to 28% from 31% as increased spending on brand building and premiumisation outpaced earnings growth in the quarter.
๐ธ Gross margin expanded by 40 basis points to 69.6%, indicating effective pricing power despite rising commodity costs.
๐ The company's board approved an interim dividend of INR 24 per share for fiscal 2026-27, payable starting November 19, 2026.
๐ข Management plans to mitigate commodity-cost volatility through cost savings initiatives and calibrated pricing strategies moving forward.
๐ Bullish signals
๐Colgate-Palmolive India delivered a strong quarterly performance with net profit rising 4.2% year over year to INR 342 crore.
๐Revenue from operations surged 12.2% to INR 1,705.7 crore, driven by double-digit sales growth in the core toothpaste portfolio.
๐ฆทThe company successfully launched Colgate MaxFresh and expanded its premium range, contributing to high-single-digit volume growth.
๐ธGross margins improved by 40 basis points to 69.6%, reflecting effective cost management and pricing strategies.
๐ The board approved a substantial interim dividend of INR 24 per share, signaling confidence in future cash flows.
๐ Risk factors
โ ๏ธEBITDA margin contracted to 28% from 31% due to higher brand-building and premiumisation spending that outpaced earnings growth.
๐ฐOperating costs and investment spending grew faster than earnings, temporarily dampening overall profitability despite revenue expansion.
Article
Colgate-Palmolive India reported robust financial performance for the quarter ended September 30, 2026, driven by double-digit sales growth and a strong profit beat. Net profit rose 4.2% year over year to INR 342 crore, while revenue from operations increased 12.2% to INR 1,705.7 crore. The company's toothpaste portfolio delivered high-single-digit volume growth, supported by the premium range and the Colgate MaxFresh product line.
Despite the top-line strength, operating efficiency faced headwinds as higher spending on brand building and premiumisation squeezed the EBITDA margin to 28% from 31%. Gross margins expanded by 40 basis points to 69.6%, but management noted that operating costs and investment spending grew faster than earnings. The company plans to address commodity-cost volatility through cost savings and calibrated pricing while continuing to invest in products and advertising.
The board approved an interim dividend of INR 24 per share for fiscal 2026-27, with payments scheduled to begin on November 19, 2026. Shareholders recorded on November 2, 2026, are eligible for this payout. This announcement follows the company's strong quarterly results and reflects its commitment to returning value to shareholders while navigating input cost pressures in the Indian consumer staples market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Colgate-Palmolive India reported robust financial performance for the quarter ended September 30, 2026, driven by double-digit sales growth and a strong profit beat. Net profit rose 4.2% year over year to INR 342 crore, while revenue from operations increased 12.2% to INR 1,705.7 crore. The company's toothpaste portfolio delivered high-single-digit volume growth, supported by the premium range and the Colgate MaxFresh product line.
Despite the top-line strength, operating efficiency faced headwinds as higher spending on brand building and premiumisation squeezed the EBITDA margin to 28% from 31%. Gross margins expanded by 40 basis points to 69.6%, but management noted that operating costs and investment spending grew faster than earnings. The company plans to address commodity-cost volatility through cost savings and calibrated pricing while continuing to invest in products and advertising.
The board approved an interim dividend of INR 24 per share for fiscal 2026-27, with payments scheduled to begin on November 19, 2026. Shareholders recorded on November 2, 2026, are eligible for this payout. This announcement follows the company's strong quarterly results and reflects its commitment to returning value to shareholders while navigating input cost pressures in the Indian consumer staples market.
๐ India revenue rose 12.2% YoY to INR 1,705.7 crore in Q3 2026.
๐ฐ Net profit grew 4.2% to INR 342 crore despite market headwinds.
๐ฆท Toothpaste volumes grew high-single-digits driven by premium range and MaxFresh launch.
โ ๏ธ EBITDA margin fell to 28% as brand spending outpaced earnings growth.
๐ Colgate-Palmolive India reported a 12.2% year-over-year increase in revenue from operations, reaching INR 1,705.7 crore for the quarter ended September 30, 2026.
๐ฐ Net profit grew 4.2% to INR 342 crore, demonstrating resilient profitability despite macroeconomic headwinds in the Indian consumer market.
๐ฆท The toothpaste portfolio achieved high-single-digit volume growth, bolstered by the premium range and the launch of Colgate MaxFresh.
โ ๏ธ EBITDA margin declined to 28% from 31% as increased spending on brand building and premiumisation outpaced earnings growth in the quarter.
๐ธ Gross margin expanded by 40 basis points to 69.6%, indicating effective pricing power despite rising commodity costs.
๐ The company's board approved an interim dividend of INR 24 per share for fiscal 2026-27, payable starting November 19, 2026.
๐ข Management plans to mitigate commodity-cost volatility through cost savings initiatives and calibrated pricing strategies moving forward.
Bullish Signals
India net profit rose 4.2% YoY to INR 342 crore.
Risk Factors
EBITDA margin fell to 28% as spending outpaced earnings.
Costs rose faster than earnings, hurting profitability.
Bullish Signals
Colgate-Palmolive India delivered a strong quarterly performance with net profit rising 4.2% year over year to INR 342 crore.
Revenue from operations surged 12.2% to INR 1,705.7 crore, driven by double-digit sales growth in the core toothpaste portfolio.
The company successfully launched Colgate MaxFresh and expanded its premium range, contributing to high-single-digit volume growth.
Gross margins improved by 40 basis points to 69.6%, reflecting effective cost management and pricing strategies.
The board approved a substantial interim dividend of INR 24 per share, signaling confidence in future cash flows.
Risk Factors
EBITDA margin contracted to 28% from 31% due to higher brand-building and premiumisation spending that outpaced earnings growth.
Operating costs and investment spending grew faster than earnings, temporarily dampening overall profitability despite revenue expansion.
Colgate-Palmolive Company (CL) has significantly outperformed the broader market and its sector peers over the past year, with shares surging 30.1% compared to the S&P 500's 13.5% gain. This strong momentum continued into 2026, where CL rose nearly 26.6% against the index's 12.3% increase, while also beating the State Street Consumer Staples Select Sector SPDR ETF (XLP) which gained 18.4% during the same period.
The company delivered robust financial results in its Q3 2026 earnings report released on October 30, with revenue increasing 4.6% year-over-year to $5.4 billion, surpassing Wall Street estimates. Adjusted earnings per share reached $0.97, also exceeding consensus expectations, driven by growth in both sales volumes and organic revenue that signals sustained consumer demand for its oral, personal, and home care products.
Analysts maintain a 'Moderate Buy' consensus rating on CL based on 22 covers, with the average price target set at $100.52, which is currently below the market price. While Barclays analyst Lauren Lieberman maintains a 'Hold' rating with a $95 target, the Street-high target of $112 suggests potential upside, and expectations for full-year 2026 EPS growth of 6% to $3.91 reflect continued confidence in the company's performance.
๐ CL shares rallied 30.1% over the past year, outperforming major indices.
๐ฐ Q3 2026 revenue rose 4.6% YoY to $5.4 billion, beating estimates.
๐ Adjusted EPS reached $0.97, topping market expectations for the quarter.
๐ฎ Analysts project full-year 2026 EPS to rise 6% to $3.91.
๐ฏ Street-high price target of $112 implies 11.4% upside from current levels.
๐ CL shares have rallied 30.1% over the past year, significantly outperforming the S&P 500 Index and the XLP consumer staples ETF.
๐ In 2026, the stock has grown by nearly 26.6%, demonstrating strong relative performance against the broader market index.
๐ฐ Q3 2026 revenue rose 4.6% year-over-year to $5.4 billion, successfully surpassing analyst consensus estimates.
๐ Adjusted EPS for the quarter reached $0.97, topping market expectations and indicating healthy profitability.
๐ Sales volumes and organic revenue both grew in Q3 2026, reflecting robust underlying demand for Colgate's product portfolio.
๐ฎ Analysts project full-year 2026 EPS to rise 6% to $3.91 on a diluted basis, building on four consecutive quarters of beats.
๐ฅ The consensus rating among 22 analysts is 'Moderate Buy', supported by ten 'Strong Buy' ratings and three 'Moderate Buys'.
๐ต The mean analyst price target stands at $100.52, which is currently below the prevailing market price.
๐ฏ The Street-high price target of $112 implies a potential 11.4% upside from current trading levels.
โ๏ธ Barclays analyst Lauren Lieberman maintains a 'Hold' rating with a specific price target of $95.
Bullish Signals
Shares surged 30.1% over the past year, outperforming S&P 500.
Stock grew 26.6% in 2026 vs broader market index.
Q3 2026 revenue rose 4.6% YoY to $5.4B, beating estimates.
Adjusted EPS hit $0.97, topping market expectations.
Analysts project full-year 2026 EPS up 6% to $3.91.
Consensus rating is 'Moderate Buy' with ten 'Strong Buys'.
Street price target of $112 implies 11.4% upside.
Risk Factors
Barclays holds CL at $95, below current price.
Mean analyst target of $100.52 is below market.
Bullish Signals
CL shares have surged 30.1% over the past year, significantly outperforming the S&P 500 Index and the XLP consumer staples ETF.
The stock has grown by nearly 26.6% in 2026, demonstrating strong relative performance against the broader market index.
Q3 2026 revenue rose 4.6% year-over-year to $5.4 billion, successfully surpassing analyst consensus estimates.
Adjusted EPS for the quarter reached $0.97, topping market expectations and indicating healthy profitability.
Sales volumes and organic revenue both grew in Q3 2026, reflecting robust underlying demand for Colgate's product portfolio.
Analysts project full-year 2026 EPS to rise 6% to $3.91 on a diluted basis, building on four consecutive quarters of beats.
The consensus rating among 22 analysts is 'Moderate Buy', supported by ten 'Strong Buy' ratings and three 'Moderate Buys'.
The Street-high price target of $112 implies a potential 11.4% upside from current trading levels.
Risk Factors
Barclays analyst Lauren Lieberman maintains a 'Hold' rating with a specific price target of $95, which is below the current market price.
The mean analyst price target of $100.52 is currently below the prevailing market price, suggesting limited immediate upside according to average consensus.
Colgate-Palmolive (CL) shares are supported by a recent Q3 2026 earnings beat and updated guidance that exceeded subdued market expectations. Major investment banks, including UBS, Morgan Stanley, and BNP Paribas, have raised their price targets to the US$108-US$112 range, citing strong execution in a challenging operating backdrop. Goldman Sachs specifically highlighted the company's ability to raise full-year 2026 guidance as evidence of robust performance.
Analyst sentiment remains mixed regarding near-term growth prospects due to specific headwinds. Piper Sandler warns of ongoing pressure in U.S. category momentum and expects continued inventory challenges as business shifts toward e-commerce and retailers adjust stock levels. While Barclays and Wells Fargo maintain Equal Weight ratings, they lifted their price targets to US$95, reflecting a balanced but cautious stance on the stock's immediate trajectory.
Simply Wall St has adjusted its fair value estimate for Colgate-Palmolive from US$98.80 to US$101.70, indicating a modest uplift in valuation. The model assumes revenue growth of 2.75% and a net profit margin expansion to 15.09%, while keeping the future P/E ratio stable at approximately 27.4x. Key strategic drivers include the company's reliance on premium oral care lines, SGPP cost savings initiatives, and AI-driven tools like Promo AI to fund reinvestment and support profitability.
๐ Colgate beat Q3 2026 earnings and raised FY26 guidance.
๐ฐ Major banks raise price targets to US$95-US$112 range.
๐ U.S. category momentum faces pressure from e-commerce shifts.
๐ค AI tools fund reinvestment while maintaining profitability margins.
โ ๏ธ Risks include North America growth slowdown and legal actions.
๐ Colgate-Palmolive beat Q3 2026 earnings expectations and raised FY26 guidance against a subdued backdrop.
๐ฐ UBS, Morgan Stanley, and BNP Paribas raised price targets to the US$108-US$112 range reflecting confidence in execution.
๐ Piper Sandler flags ongoing pressure in U.S. category momentum and inventory headwinds from e-commerce shifts.
โ๏ธ Barclays and Wells Fargo maintain Equal Weight ratings but lifted price targets to US$95.
๐ต Simply Wall St raised its fair value estimate for CL from US$98.80 to US$101.70.
๐ Revenue growth assumptions are set at 2.75% with net profit margins adjusted up to 15.09%.
๐ค The company leverages SGPP cost savings and AI tools like Promo AI to fund reinvestment and maintain profitability.
โ ๏ธ Key risks include softer category growth in North America and ongoing legal action over toothpaste tube recyclability.
Piper Sandler warns of U.S. category momentum pressure and inventory headwinds.
Barclays and Wells Fargo maintain Equal Weight ratings with cautious stance.
Bullish Signals
Colgate-Palmolive delivered a Q3 2026 earnings beat and raised FY26 guidance against subdued expectations, signaling strong execution.
Major analysts including UBS, Morgan Stanley, and BNP Paribas increased price targets to the US$108-US$112 range due to better-than-expected sales and margin performance.
Goldman Sachs highlighted the earnings beat and guidance raise as signs of strong execution in a challenging operating environment.
Risk Factors
Piper Sandler warns of ongoing pressure in U.S. category momentum and expects continued inventory headwinds as business shifts to e-commerce.
Barclays and Wells Fargo maintain Equal Weight ratings, indicating a balanced but cautious stance despite lifting price targets.
Colgate-Palmolive (NYSE:CL) is highlighted as a top-tier 'Dividend King' stock, having increased its dividend for 63 consecutive years since 1962. The company maintains dominant market positions in oral care and pet nutrition, holding a 41.3% share of the toothpaste market and a strong presence in the Hill's Science Diet brand. Its business model relies on essential consumer habits that provide stable revenue streams regardless of economic conditions.
In September 2026, Colgate announced a quarterly dividend of $0.53 per share, resulting in an annual yield of approximately 2.5% at a share price of $86. While the company generated robust operating cash flow of $1.742 billion in the first half of 2026, its earnings payout ratio stands at roughly 84%, indicating that a significant portion of reported profits is distributed to shareholders rather than reinvested.
Investors view CL as a defensive play for consistency rather than high current income, though the stock trades at a premium with a forward P/E of 21x. Analysts note that while the company offers reliable growth and brand strength, its valuation leaves little room for earnings declines. The article suggests CL is a solid choice for long-term portfolios prioritizing dividend safety over immediate yield or high-growth potential.
๐ Colgate-Palmolive increased dividend for 63 consecutive years since 1895.
๐ฆท Company holds 41.3% toothpaste market share and strong manual brush position.
๐ฐ September 2026 quarterly dividend of $0.53 yields ~2.5% at $86 price.
โ๏ธ Earnings payout ratio is 84%, limiting funds for business expansion.
๐ Forward P/E multiple is 21x, implying less attractive earnings yield vs bonds.
๐ Colgate-Palmolive has increased its dividend for 63 consecutive years, earning its status as a 'Dividend King' with an uninterrupted payment history dating back to 1895.
๐ฆท The company maintains a dominant 41.3% market share in the toothpaste sector and holds a significant position in the manual toothbrush market.
๐พ Hill's Science Diet is a key growth asset within the Pet Nutrition segment, catering to pet owners willing to pay premium prices for health-focused nutrition.
๐ฐ In September 2026, the company declared a quarterly dividend of $0.53 per share, providing an annual yield of approximately 2.5% at a stock price of $86.
๐ Operating cash flow reached $1.742 billion in the first six months of 2026, demonstrating sufficient liquidity to support regular dividend payments and business reinvestment.
โ๏ธ The earnings payout ratio is currently around 84%, meaning a large portion of reported profits are paid out as dividends rather than retained for expansion.
๐ Colgate-Palmolive trades at a forward P/E multiple of approximately 21x, reflecting a premium valuation for its mature consumer goods business and stable cash flows.
๐ Hedge funds rank CL among the top 10 'Dividend King' stocks, though it trails nine other companies on the specific list mentioned in the analysis.
๐ Compared to Procter & Gamble (PG), Colgate is viewed as a cheaper investment with similar forward P/E multiples but expected faster earnings growth.
โ ๏ธ The high valuation implies an earnings yield of about 4.8%, which may be less attractive than government bonds if interest rates remain elevated or stable.
Bullish Signals
Dividends increased for 63 consecutive years since 1895.
Holds 41.3% toothpaste market share with strong brands.
Hill's Science Diet is a profitable premium pet food asset.
Operating cash flow of $1.742 billion supports dividends.
Hedge funds rank CL top 10 'Dividend King' stock.
Risk Factors
Trades at premium 21x forward P/E with limited downside buffer.
Bullish Signals
Colgate-Palmolive has a proven track record of increasing dividends for 63 consecutive years, establishing it as a reliable 'Dividend King' with an uninterrupted payment history since 1895.
The company holds a dominant 41.3% market share in the toothpaste market and maintains strong brand recognition that creates high barriers to entry for competitors.
Hill's Science Diet is a highly profitable asset within the Pet Nutrition segment, benefiting from consumers' willingness to pay premium prices for veterinary-recommended pet food.
Operating cash flow of $1.742 billion in the first half of 2026 provides management with ample scope to sustain dividend payments and fund business reinvestment initiatives.
Hedge funds consider CL one of the top 10 'Dividend King' stocks, validating its status as a premier defensive investment for long-term portfolios.
Risk Factors
The stock trades at a premium valuation with a forward P/E of approximately 21x, leaving little room for earnings to decline without significantly impacting the share price.
With a forward P/E of 21x and an implied earnings yield of 4.8%, the stock may be less attractive than government bonds for investors seeking competitive returns in a stable rate environment.
The current dividend yield of approximately 2.5% is considered conservative and insufficient for investors requiring substantial immediate income compared to higher-yielding alternatives.
Colgate-Palmolive (Pakistan) Limited has signed an asset purchase agreement with Procter & Gamble Pakistan to acquire land, a manufacturing facility, and related assets located at Port Qasim in Karachi. The deal was formalized on October 28, 2026, following an initial disclosure made in May of the same year regarding the proposed acquisition.
This transaction directly follows Procter & Gamble's strategic decision to wind down its local manufacturing and commercial operations in Pakistan as part of a broader global restructuring program. P&G plans to transition to a third-party distributor model to continue serving consumers, while Colgate-Palmolive steps in to acquire the physical infrastructure.
The completion of this asset acquisition is currently subject to regulatory approval from the Competition Commission of Pakistan (CCP). Colgate-Palmolive Pakistan, originally incorporated as National Detergents Limited in 1977 and renamed in 1990, is primarily engaged in the manufacture and sale of detergents and personal care products.
The acquisition represents a significant strategic shift for the local market, allowing Colgate-Palmolive to expand its manufacturing footprint while P&G exits the region. This move aligns with P&G's global efforts to cut non-manufacturing jobs and exit specific categories in individual markets to accelerate growth and value creation.
๐ค Colgate-Palmolive acquires P&G Pakistan manufacturing assets at Port Qasim.
๐ Deal finalized October 28, 2026, following May 2026 disclosure.
โ๏ธ Transaction completion contingent on Competition Commission of Pakistan approval.
๐ Colgate secures base as P&G shifts to third-party distributor model.
๐งผ Company manufactures detergents and personal care products since 1977.
๐ค Colgate-Palmolive (Pakistan) Limited has signed an agreement to acquire Procter & Gamble Pakistan's manufacturing assets at Port Qasim, Karachi.
๐ The transaction was finalized on October 28, 2026, following a May 2026 disclosure regarding the proposed deal.
๐ญ The acquisition includes land, a manufacturing facility, and related assets previously operated by P&G Pakistan.
โ๏ธ Completion of the asset purchase is contingent upon approval from the Competition Commission of Pakistan (CCP).
๐ This deal follows P&G's decision to wind down its local operations in Pakistan as part of a global restructuring initiative.
๐ P&G plans to transition to a third-party distributor model while Colgate-Palmolive secures the manufacturing base.
๐งผ Colgate-Palmolive Pakistan is primarily engaged in the manufacture and sale of detergents and personal care products.
๐ข The target company was originally incorporated as National Detergents Limited in 1977 and renamed in 1990.
Bullish Signals
Secures manufacturing asset at Port Qasim, Karachi.
Expands local production capabilities via strategic acquisition.
Risk Factors
Deal faces CCP regulatory approval delays or termination risk.
Bullish Signals
Colgate-Palmolive secures a strategic manufacturing asset at Port Qasim, Karachi, expanding its local production capabilities.
The acquisition allows Colgate-Palmolive to capitalize on P&G's exit from the Pakistani market, potentially gaining significant market share in detergents and personal care.
Risk Factors
The transaction remains subject to regulatory approval from the Competition Commission of Pakistan (CCP), introducing potential delays or deal termination risk.
Colgate-Palmolive (CL) faces a critical valuation test ahead of its third-quarter earnings report on October 30, having surged 21.87% year-to-date despite underlying weakness in its core North American market. The stock currently trades at approximately 24x forward 2026 EPS, a demanding multiple for a company guiding only 1% to 4% organic growth. This rally has outpaced the business fundamentals, which show four consecutive quarters of declining net sales in North America driven by volume contraction and retailer inventory cuts.
The article highlights significant headwinds including rising oil prices, which have climbed to $107.89 per barrelโwell above management's $90 reference priceโthreatening back-half gross margins. While the company recently beat EPS estimates for six straight quarters with a 4.9% revenue increase, this was driven by pricing power rather than volume growth. Management warns that the second half will be more volume-driven but faces challenges from private label competition and a lack of expected foreign exchange benefits in Latin America.
Analyst sentiment has turned cautious, evidenced by three downward revisions to FY2026 EPS consensus estimates over the past 30 days with zero upward revisions. Investors are scrutinizing whether Colgate can prove sequential improvement in its U.S. market and maintain margins against higher input costs. The stock's status as a 'safe haven' based on its long history of dividend increases and global toothpaste market share is being weighed against the risk that the current premium may not be justified if North American contraction continues.
The upcoming earnings report will be pivotal in determining if the recent rally is sustainable or if it exposes how much of the stock's value rests on reputation rather than immediate financial performance. Management has indicated that cost pressures and tariffs will peak in the back half, but specifically flagged Q4 risk regarding oil prices. If costs rise while North America continues to contract, the earnings report could reveal that a significant portion of the rally is priced in without corresponding operational improvements.
๐ CL trades at high 24x multiple despite weak 1-4% organic growth guidance.
๐บ๐ธ North American sales fell 3.0% for fourth straight quarter due to volume drops.
๐ข๏ธ Oil prices above $90 reference threaten margins with zero recent EPS revisions.
๐ฐ Base EPS beat consensus at $0.99 driven by pricing power, not volume.
โ ๏ธ Management warns non-linear recovery and upcoming Q3 report is critical for valuation.
๐ CL stock has surged 21.87% year-to-date but trades at ~24x 2026 EPS, a demanding multiple for a company guiding just 1% to 4% organic growth.
๐บ๐ธ North America net sales fell 3.0% for the fourth straight quarter as volume dropped 3.9% due to retailer inventory cuts and lost market share.
๐ข๏ธ Oil prices climbed to $107.89 per barrel, significantly above management's $90 reference price, threatening back-half margins with zero upward EPS revisions in the last 30 days.
๐ฐ Colgate posted Base Business EPS of $0.99 beating consensus on revenue of $5.36B (+4.9% YoY) driven by pricing power rather than volume growth.
๐ Gross margin expanded 140 bps to 61.5% even as advertising expenses rose 15% to $777M, highlighting the reliance on price increases.
โ ๏ธ Management warned that fixing North American issues will not be linear and expects a volume-driven second half after pricing carried the first half.
๐ Analysts have reduced their outlook with three downward revisions to FY2026 EPS consensus estimates and zero upward revisions over the past month.
๐ The company does not expect the same Latin American FX benefit it previously relied upon, adding pressure to global growth targets.
๐ฆท Colgate maintains a 41.3% global toothpaste share and has increased its dividend for 63 consecutive years, supporting its 'safe-haven' investor appeal.
๐ The upcoming Q3 earnings report on Oct. 30 will be critical to validate the stock's premium valuation against rising oil costs and U.S. market contraction.
Bullish Signals
Beat EPS six quarters; Base EPS $0.99 vs $0.95 consensus.
Risk Factors
North America sales declined 3.0% for four consecutive quarters.
Oil prices at $107.89/barrel create significant margin pressure.
Analyst sentiment deteriorated with three downward EPS revisions.
Private label exits in U.S. pet category drag volume.
Management warns operational improvements will not be linear.
Bullish Signals
Colgate-Palmolive beat EPS estimates for six consecutive quarters with Base Business EPS of $0.99 versus a $0.95 consensus.
The company achieved revenue growth of 4.9% year-over-year to $5.36B, demonstrating pricing power in a challenging environment.
Gross margin expanded by 140 basis points to 61.5%, indicating effective cost management despite rising advertising spend.
The stock holds a premium valuation at ~24x forward earnings, reflecting its status as a defensive safe-haven asset with 63 consecutive years of dividend increases.
Colgate maintains a dominant 41.3% global market share in the toothpaste category, providing a strong competitive moat.
Risk Factors
North America net sales have declined by 3.0% for four consecutive quarters due to volume contraction and retailer inventory cuts.
Oil prices surged to $107.89 per barrel, well above management's $90 reference price, creating significant margin pressure for the back half of the year.
Analyst sentiment has deteriorated with three downward revisions to FY2026 EPS consensus estimates and zero upward revisions in the last 30 days.
The company faces a volume drag from private label exits in the U.S. pet category, estimated at 200 basis points.
Management warned that operational improvements in North America will not be linear, suggesting continued execution challenges.
Rising oil costs and tariffs are expected to peak in the back half, specifically highlighting Q4 risk for gross margin outlooks.
The article compares Celsius Holdings (CELH) and Colgate-Palmolive (CL), contrasting Celsius's high-growth functional beverage strategy against Colgate's stable consumer staples model. It highlights that Celsius relies heavily on a distribution partnership with Pepsi, which accounted for nearly 43.2% of its total net revenue as of December 31, 2025, introducing significant customer concentration risk.
Financial performance data reveals Celsius generated $2.5 billion in FY 2025 revenue, an 85.5% increase, but reported a net income decline to approximately $108 million due to expansion costs and brand integration. Conversely, Colgate-Palmolive reported steady growth with nearly $20.4 billion in revenue and $2.1 billion in net income, maintaining its status as a Dividend King with 63 consecutive years of dividend increases.
The author concludes that despite Celsius's attractive valuation metrics and explosive stock price history, Colgate-Palmolive is the preferred investment due to its defensive nature and consistent payouts. The text notes Celsius shares are down nearly 54% over the last 12 months while Colgate shares rose 22%, outperforming the S&P 500, and cites Motley Fool analyst recommendations favoring Colgate's stability in uncertain economic times.
๐ Celsius FY2025 revenue surged 85.5% to $2.5 billion.
โ ๏ธ Nearly 43.2% of Celsius revenue depends on partner Pepsi.
๐ Motley Fool analysts excluded Celsius from their top 10 buys.
๐ Celsius Holdings reported FY 2025 revenue of $2.5 billion, representing an 85.5% increase year-over-year.
โ ๏ธ Nearly 43.2% of Celsius's total net revenue came from its primary partner, Pepsi, as of December 31, 2025.
๐ฐ Colgate-Palmolive generated $2.1 billion in net income during FY 2025 on a revenue base of nearly $20.4 billion.
๐ Celsius stock price has declined by approximately 54% over the last 12 months despite recent top-line growth.
๐ Colgate-Palmolive shares have increased by nearly 22%, outperforming both Celsius and the S&P 500's 14.3% return.
๐ Colgate-Palmolive has increased its dividend payout for 63 consecutive years, qualifying it as a Dividend King.
โ๏ธ The article identifies significant customer concentration risk for Celsius due to its heavy dependency on Pepsi for distribution and strategy.
๐ก๏ธ Colgate-Palmolive faces risks related to macroeconomic instability, inflationary pressures, and currency fluctuations across its global operations.
๐ Motley Fool analysts explicitly excluded Celsius Holdings from their list of 10 best stocks to buy now, favoring Colgate instead.
Bullish Signals
Dividend King status with 63 consecutive years of increases.
FY 2025 net income reached $2.1 billion on $20.4B revenue.
Shares rose 22% in 12 months, beating S&P 500.
Risk Factors
Inflation and currency hikes raise raw material and labor costs.
Fierce competition forces costly digital retail adaptations.
Bullish Signals
Colgate-Palmolive has increased its dividend payout for 63 consecutive years, establishing a strong track record as a Dividend King.
The company generated approximately $2.1 billion in net income during FY 2025, demonstrating robust profitability on a revenue base of nearly $20.4 billion.
Colgate shares have risen by nearly 22% over the last 12 months, significantly outperforming the S&P 500's 14.3% return and rival Celsius Holdings.
Risk Factors
Inflationary pressures and currency fluctuations can drive up costs for raw materials, logistics, and labor across different regions.
Colgate-Palmolive faces vigorous competition from multinational brands and private-label products requiring constant adaptation to the digital retail landscape.
This article compares Clorox (CLX) and Colgate-Palmolive (CL) as income stocks, concluding that while Clorox offers a higher yield of 5.89%, its financial health is deteriorating. The stock has fallen 22% over the past year, and management admits the current dividend payout is 'elevated' relative to earnings and cash flow.
Clorox faces significant headwinds including a 38% drop in operating cash flow, a sharp decline in gross margins to 41.3%, and substantial debt liabilities of $7.542B following the GOJO/Purell acquisition. Management expects inflation costs to exceed $200 million in fiscal 2027, creating pressure on future dividend sustainability.
In contrast, Colgate-Palmolive is presented as a safer retirement core with a 63-year track record of dividend increases and robust cash generation of $3.6B in free cash flow for 2025. The company has raised its Base Business EPS outlook to mid-single digits and maintains a lower beta, making it the preferred choice for investors prioritizing stability over high yield.
๐ CL stock fell 22% annually, artificially expanding dividend yield from a lower base.
๐ธ CL operating cash flow dropped 38% to $612M, threatening its $5.00 annual dividend.
๐ CL Q4 gross margin contracted 520 bps to 41.3%.
๐ฆ CL carries $7.542B liabilities vs only $252M equity post-GOJO acquisition.
๐ Analysts rate CL with two sell/strong sell ratings versus Colgate's zero sells.
๐ Clorox's stock price fell 22% over the past year, causing its dividend yield to expand artificially from a lower base.
๐ธ Clorox's operating cash flow dropped 38% to $612M in fiscal 2026, raising concerns about the ability to sustain its $5.00 annual dividend.
๐ Clorox's fourth-quarter gross margin contracted significantly to 41.3%, down 520 basis points from the prior year.
๐ฐ Colgate-Palmolive generated $3.6B in free cash flow in 2025, providing a strong buffer for shareholder returns.
๐ Colgate has raised its dividend for 63 consecutive years, establishing itself as a Dividend Aristocrat with a long-term safety record.
๐ก๏ธ Colgate-Palmolive's Base Business EPS growth outlook was raised to mid-single digits following strong Latin America sales growth of 13.7%.
๐ Analyst sentiment favors Colgate, which has zero sell ratings compared to Clorox's two sell and two strong sell ratings.
๐ฆ Clorox carries $7.542B in total liabilities against only $252M in shareholders' equity following the GOJO acquisition.
Bullish Signals
Generated $3.6B free cash flow in fiscal 2025.
Raised dividend for 63 consecutive years as Aristocrat.
Raised EPS outlook on 13.7% Latin America sales growth.
Lower beta of 0.322 reduces price volatility.
Risk Factors
Yield of 5.89% may be less attractive than Colgate-Palmolive's 2.27%.
Higher 21x valuation vs 15x limits upside potential compared to alternatives.
Bullish Signals
Colgate-Palmolive generated $3.6B in free cash flow during fiscal 2025, demonstrating strong liquidity for shareholder returns.
The company has increased its dividend payout for 63 consecutive years, qualifying it as a Dividend Aristocrat with a proven track record.
Colgate raised its Base Business EPS growth outlook to mid-single digits following robust sales growth in Latin America of 13.7%.
The company maintains a lower beta of 0.322, indicating less stock price volatility compared to peers like Clorox.
Risk Factors
While the article primarily discusses Clorox's risks, it notes that Colgate-Palmolive has a significantly lower yield of 2.27% compared to Clorox's 5.89%, which may be less attractive for pure income seekers.
The company does not have any analyst sell ratings, but the article implies that its lower yield and higher valuation multiple (21x forward earnings vs Clorox's 15x) might limit upside potential compared to cheaper alternatives.
Company updatePremium pricingAI-generated analysis
Colgate-Palmolive (CL) is evaluated as fairly valued with a forward P/E of 22x, supported by durable franchises in oral care and pet nutrition which accounted for roughly two-thirds of 2025 revenue. The company reported a 41.3% global toothpaste market share by value through Q2 2026, leveraging scale to protect margins despite higher input costs and advertising expenses.
A key strategic focus is the transition within its Hill's pet nutrition division, which is replacing private-label production with branded nutrition to improve per-unit profitability. While therapeutic nutrition segments like Prescription Diet showed pricing and volume growth in Q2 2026, management faces the challenge of sustaining this momentum against broader category slowdowns and rising marketing costs.
Financial performance was impacted by a $919 million pretax skin-health impairment recorded in 2025, primarily due to weakened prospects in China. Excluding this charge, Base Business EPS is expected to grow in the mid-single digits in 2026, driven by pricing power and productivity gains that offset inflation and restructuring charges totaling an estimated $350 million to $550 million.
Analysts project roughly 6% adjusted EPS growth for 2027, though sustaining the current valuation requires organic sales to outpace advertising spend and overhead. The investment case hinges on Hill's ability to broaden branded volume growth and generate cash flow that supports distributions without requiring additional borrowing or dilution.
๐ CL trades at 22x forward P/E with improving earnings outlook below peak growth.
๐ฆด Holds 41.3% global toothpaste market share driving recurring sales through Q2 2026.
๐พ Hill's pet nutrition transitions to branded products capturing higher margins and volume.
๐ฐ GAAP profit hit by $919M skin-health impairment; base EPS expected mid-single-digit growth.
๐ Organic sales slowed to 1.4% in 2025 due to demand weakness and cost pressures.
๐ Colgate-Palmolive trades at a forward P/E of 22x, reflecting a valuation between its 2024 and 2025 historical levels as earnings outlook improves but remains below peak growth rates.
๐ฆด The company holds a 41.3% global toothpaste market share by value through Q2 2026, supported by familiar brands and broad distribution networks that drive recurring sales.
๐พ Hill's pet nutrition is transitioning from private-label exit to branded nutrition to capture higher margins, with Prescription Diet showing both pricing and volume growth in the second quarter.
๐ฐ Reported GAAP profit was depressed by a $919 million pretax skin-health impairment in 2025, though management expects mid-single-digit Base Business EPS growth in 2026 excluding such charges.
๐ Organic sales grew 7.4% in 2024 but slowed to 1.4% in 2025 due to category demand weakness and material cost pressures, necessitating a recovery in volume to spread factory costs.
๐ Second-quarter organic sales rose 2.1% with pricing up 3.9%, though volume declined 1.8%; management notes volume would have been flat without the private-label exit.
๐ ๏ธ The restructuring program carries estimated cumulative pretax charges of $350 million to $550 million, with 80-90% requiring cash, substantially all expected by the end of 2028.
๐ Operating margin declined to 22.5% from 22.9% in Q2 due to a 2.6 point rise in selling and administrative expenses, predominantly driven by increased advertising spend.
๐ต First-half operating cash flow generated $1.742 billion, with capital expenditures of $266 million leaving approximately $1.48 billion, which was largely consumed by dividends and repurchases.
๐ Colgate-Palmolive is included in Insider Monkey's list of 10 Best Dividend Kings To Buy According to Hedge Funds, highlighting its status as a reliable income stock.
Bullish Signals
41.3% global toothpaste market share by value through Q2 2026.
Hill's delivered pricing and volume growth in the second quarter.
Management expects mid-single-digit Base Business EPS growth in 2026.
Second-quarter adjusted net income increased 6%, while EPS rose 8%.
Risk Factors
$919M impairment recorded in 2025 due to weakened China prospects.
Bullish Signals
Colgate-Palmolive holds a dominant 41.3% global toothpaste market share by value through Q2 2026, supported by durable franchises and broad distribution.
Hill's Prescription Diet delivered both pricing and volume growth in the second quarter, demonstrating that therapeutic demand can withstand higher prices.
Management expects mid-single-digit Base Business EPS growth in 2026, supported by pricing power and productivity gains despite higher input costs.
Second-quarter adjusted net income increased 6%, while EPS rose 8% as fewer shares divided the profit due to share buybacks.
Hill's gross margin improved 2.4 percentage points through productivity, pricing, and mix adjustments in the second quarter.
The company generated $1.742 billion of first-half operating cash, with net cash retained after distributions increasing from $1.25 billion to about $1.48 billion.
Risk Factors
Reported GAAP profit was depressed by a $919 million pretax skin-health impairment recorded in 2025 after business prospects weakened, particularly in China.
Organic sales growth slowed to 1.4% in 2025 from 7.4% in 2024 as category demand weakened and material costs pressured margins.
Operating margin declined to 22.5% from 22.9% in Q2 due to a 2.6 point rise in selling and administrative expenses, predominantly because of increased advertising.
The restructuring program carries estimated cumulative pretax charges of $350 million to $550 million, with 80-90% requiring cash payments.
Working-capital movements absorbed $137 million less cash than a year earlier, as improved payables and other movements outweighed additional money tied up in inventories.
Sustaining the current valuation requires sales to outgrow advertising and overhead so that better manufacturing economics reach shareholders.
Colgate-Palmolive Company (CL), a global consumer staples leader with a $71.7 billion market cap, is preparing to release its fiscal Q3 2026 earnings results. The company maintains strong positions in oral care, personal care, home care, and pet nutrition across over 200 countries, characterized by high brand loyalty and steady demand.
Analysts forecast the company to report an adjusted EPS of $0.92 for the upcoming quarter, representing a 1.1% increase from the year-ago period. For fiscal 2026, projected adjusted EPS stands at $3.87, with expectations of further growth to $4.07 in fiscal 2027. The company has successfully exceeded Wall Street's earnings estimates for the last four consecutive quarters.
Shares of Colgate-Palmolive have surged 18.3% over the past 52 weeks, significantly outperforming both the S&P 500 and the Consumer Staples Select Sector SPDR ETF. This momentum is driven by improving earnings expectations, resilient demand for essential products, and a recovery in oral-care market share following a challenging 2025.
The company boasts a robust financial profile with an average gross margin of 60.5% and a free cash flow margin of 17.6% over the past two years. On September 17, Colgate-Palmolive declared a quarterly dividend of $0.53 per share, payable on November 13, 2026, continuing its uninterrupted dividend history dating back to 1895.
๐ Analysts forecast adjusted EPS of $0.92 for fiscal Q3 2026 results.
๐ Shares soared 18.3% over the past 52 weeks outpacing S&P 500.
๐ฐ Quarterly dividend declared at $0.53 per share payable November 13, 2026.
๐ก๏ธ Oral-care market share recovered after 2025 with high brand loyalty.
๐ Average price target of $97.19 suggests 4.8% potential upside.
๐ Colgate-Palmolive is set to announce fiscal Q3 2026 results with analysts forecasting an adjusted EPS of $0.92.
๐ The company has exceeded Wall Street's earnings estimates in each of the last four quarters.
๐ Shares have soared 18.3% over the past 52 weeks, outpacing the S&P 500 and XLP ETF returns.
๐ฐ Analysts project adjusted EPS growth to $4.07 by fiscal 2027, up from $3.69 in fiscal 2025.
๐ก๏ธ The company benefits from high brand loyalty and a recovery in oral-care market share after 2025.
๐ต Colgate-Palmolive declared a quarterly dividend of $0.53 per share payable on November 13, 2026.
๐ Analysts maintain an average price target of $97.19, suggesting potential upside of 4.8% from current levels.
๐ญ The company maintains a powerful business model with an average gross margin of 60.5% over the past two years.
๐ง Free cash flow margins have averaged 17.6% over the last two years, supporting growth and shareholder returns.
๐ Investor confidence has returned in 2026 driven by resilient demand for everyday essentials.
Bullish Signals
Shares surged 18.3% over past 52 weeks.
Beat earnings estimates for four consecutive quarters.
Projected adjusted EPS reaches $4.07 by 2027.
Declared quarterly dividend of $0.53 per share.
Bullish Signals
Shares of Colgate-Palmolive have surged 18.3% over the past 52 weeks, significantly outperforming the S&P 500 and Consumer Staples ETF.
The company has exceeded Wall Street's earnings estimates in each of the last four consecutive quarters.
Analysts project adjusted EPS growth to $4.07 by fiscal 2027, indicating sustained profitability.
Colgate-Palmolive declared a quarterly dividend of $0.53 per share, continuing an uninterrupted history dating back to 1895.
The company has regained investor confidence in 2026 with improving earnings expectations and resilient demand.
A recovery in oral-care market share following a challenging 2025 strengthens the company's competitive position.
The business model supports ample room to invest in growth with an average gross margin of 60.5%.
Colgate-Palmolive (CL) is currently trading at approximately US$89.95 per share, a price point that analysts are evaluating against the company's robust historical cash flow performance. Over the past five years, the business has returned 35.5% to shareholders, driven by steady consumer demand and strong cash conversion capabilities inherent in its household and personal care portfolio.
A Discounted Cash Flow (DCF) analysis utilizing a latest twelve-month free cash flow of roughly $3.85 billion suggests that the company's intrinsic value is meaningfully higher than its current market price. The model projects gradual growth in free cash flow over the coming decade, fitting the profile of a mature consumer products business where reliability of cash generation is paramount.
Simply Wall St presents two distinct valuation narratives for CL: a bullish case suggesting the stock is 9% undervalued due to potential pricing power and mix improvements from premium product lines like Optic White Pro Series; conversely, a bearish or neutral case argues the stock is roughly fairly valued, warning against double-counting margin adjustments which could otherwise overstate fair value by approximately 45%.
๐ CL returned 35.5% to shareholders over past five years.
๐ DCF analysis suggests intrinsic worth above current US$89.95 price.
๐ Premiumization of core oral care lines drives potential upside.
โ ๏ธ Normalizing margins could overstate fair value by roughly 45%.
๐ Colgate-Palmolive has returned 35.5% to shareholders over the past five years, demonstrating a strong cash engine supported by steady consumer demand.
๐ฐ The company generated approximately $3.85 billion in latest twelve-month free cash flow, providing a solid anchor for valuation models.
๐ A DCF analysis indicates that projected future cash flows support an intrinsic worth meaningfully above the current share price of US$89.95.
๐ The bullish narrative attributes potential upside to expansion and premiumization of core oral care lines like Colgate Total and Optic White Pro Series.
โ ๏ธ The bearish narrative warns that normalizing margins while leaving future multiples at GAAP-derived figures could overstate fair value by roughly 45%.
๐ท๏ธ Simply Wall St's community analysis concludes that the bullish view sees more upside in the current price than the cautious, fair value perspective.
Bullish Signals
Delivered 35.5% shareholder return over five years.
Risk Factors
Valuation may overstate fair value by ~45% due to margin adjustments.
Growth expected to be gradual, not aggressive step changes.
Bullish Signals
Colgate-Palmolive has delivered a solid run over the past few years with a 35.5% shareholder return over five years.
The company relies on steady consumer demand and strong cash conversion from household and personal care brands to support consistent reinvestment and payouts.
A DCF model based on $3.85 billion in latest twelve-month free cash flow suggests the stock is undervalued relative to its future cash generation potential.
The bullish narrative identifies 9% undervaluation driven by expansion and premiumization of core oral care lines like Colgate Total and Optic White Pro Series.
Risk Factors
A cautious valuation view suggests the stock is roughly fairly valued, noting that double-counting margin adjustments could overstate fair value by roughly 45%.
The business profile is that of a mature consumer products company where growth is expected to be gradual rather than aggressive step changes.
Colgate-Palmolive reported strong second-quarter financial results, with revenue rising 4.90% year-over-year to USD 5.36 billion. The company beat earnings per share consensus, reporting USD 0.99 versus the expected USD 0.95, driven by solid operational execution in its consumer staples business.
Despite the positive quarterly performance, Bank of America lowered its price target for Colgate-Palmolive stock from USD 102.00 to USD 100.00 on October 9, 2026. The analyst maintained a Buy rating, suggesting that while the company's fundamentals remain sound, current valuation metrics may not fully justify the higher price target previously set.
The company maintains a robust balance sheet with USD 1.4 billion in cash and cash equivalents as of June 30, 2026, and continues to return capital to shareholders through a quarterly dividend of USD 0.53. Trading data indicates the stock was up approximately 1.52% on October 13, 2026, reflecting market interest in its recent earnings beat.
๐ Q2 revenue rose 4.90% to USD 5.36 billion.
๐ฐ EPS hit USD 0.99, beating estimates by four cents.
๐ Bank of America lowered price target to USD 100.
๐ต Cash on hand stands at USD 1.4 billion.
๐ข Market cap is approximately USD 72.0 billion.
๐ Colgate-Palmolive reported Q2 revenue of USD 5.36 billion, representing a 4.90% increase year-over-year.
๐ฐ Earnings per share reached USD 0.99, beating the analyst consensus estimate of USD 0.95 by four cents.
๐ Bank of America cut its price target for CL from USD 102.00 to USD 100.00 while retaining a Buy rating.
๐ต The company holds USD 1.4 billion in cash and cash equivalents as of June 30, 2026.
๐ A quarterly dividend of USD 0.53 was declared with an October 20, 2026 record date.
๐ข The stock trades under the NYSE ticker CL with a market capitalization of approximately USD 72.0 billion.
Bullish Signals
Revenue grew 4.90% year-over-year in Q2.
EPS beat expectations at USD 0.99.
Holds USD 1.4 billion cash.
Risk Factors
Bank of America cut price target from $102 to $100.
Bullish Signals
Colgate-Palmolive achieved a Q2 revenue growth of 4.90% year-over-year, demonstrating resilient demand in its core consumer staples portfolio.
The company beat quarterly earnings per share expectations with a reported USD 0.99 versus the USD 0.95 consensus forecast.
Colgate-Palmolive maintains a strong liquidity position with USD 1.4 billion in cash and cash equivalents on hand as of June 30, 2026.
Risk Factors
Bank of America reduced its price target for the stock from USD 102.00 to USD 100.00, indicating a slight adjustment in valuation expectations despite recent earnings beats.
Colgate-Palmolive (NYSE:CL) is analyzed as a top-tier 'Dividend King' stock, having increased its dividend for 63 consecutive years since 1963. The company derives revenue from three main segments: Oral Care, Personal Care/Home Care, and Pet Nutrition, with Hill's Science Diet being a key asset in the pet sector.
Financial metrics indicate that CL maintains a strong market position, holding a 41.3% share of the toothpaste market and 32.7% of the manual toothbrush sector as of Q2 2026. The company generated $1.742 billion in operating cash flow during the first half of 2026, supporting its ability to sustain dividend payments while managing capital expenditures.
Despite its robust fundamentals and predictable business model driven by essential consumer habits, CL trades at a premium valuation with a forward P/E ratio of approximately 21x. The current yield is around 2.5%, which the article suggests may be insufficient for investors seeking high immediate income compared to government bonds or other dividend stocks.
Analysts note that while CL offers consistency and brand strength, its stock price carries a significant premium that limits upside potential if earnings growth slows. The company is viewed as a solid long-term hold for portfolios prioritizing stability over high yield, though investors are cautioned about valuation risks relative to peers like Procter & Gamble.
๐ CL dividend increased for 63 consecutive years since 1895.
๐ฆท Holds 41.3% toothpaste market share in Q2 2026.
๐ฐ Operating cash flow hit $1.742 billion in first half of 2026.
๐ Trades at 21x forward P/E with limited upside potential.
๐ต Current dividend yield is roughly 2.5% near $86 share price.
๐ Colgate-Palmolive has increased its dividend for 63 consecutive years, earning its status as a 'Dividend King' with an uninterrupted payment history dating back to 1895.
๐ฆท The company maintains dominant market share in oral care, holding 41.3% of the toothpaste market and 32.7% of the manual toothbrush sector in Q2 2026.
๐พ Hill's Science Diet is a major growth driver within the Pet Nutrition segment, capitalizing on consumers' willingness to pay premium prices for pet health.
๐ฐ Operating cash flow reached $1.742 billion in the first six months of 2026, providing ample liquidity for dividend payments and business reinvestment.
๐ The stock trades at a forward P/E of approximately 21x, reflecting a substantial premium valuation that limits potential upside if earnings growth decelerates.
๐ต CL offers a current dividend yield of roughly 2.5% based on a share price near $86, which is lower than yields available in the broader bond market.
๐ The earnings payout ratio stands at about 84%, indicating that a large portion of reported profits is distributed to shareholders rather than retained for growth.
โ๏ธ Compared to Procter & Gamble (PG), Colgate-Palmolive is considered a cheaper investment despite similar forward P/E multiples, as it is expected to grow faster.
๐ก๏ธ The business model relies on essential daily habits like brushing teeth and cleaning homes, providing a stable revenue stream resilient to economic downturns.
Bullish Signals
Dividend increased 63 consecutive years since 1963.
Holds 41.3% toothpaste market share.
Hill's Science Diet is highly profitable.
Operating cash flow $1.742B in H1 2026.
Viewed as top-tier Dividend King by hedge funds.
Risk Factors
Trades at 21x forward P/E, a substantial premium.
Dividend yield of 2.5% is conservative for income investors.
High valuation risks wiping out gains on price falls.
Bullish Signals
Colgate-Palmolive has increased its dividend for 63 consecutive years since 1963, establishing a robust track record of shareholder returns.
The company holds a commanding 41.3% market share in the toothpaste sector and 32.7% in manual toothbrushes, ensuring stable revenue from essential products.
Hill's Science Diet is a highly profitable pet nutrition brand that benefits from consumers' willingness to pay premium prices for veterinary-recommended food.
Operating cash flow of $1.742 billion in H1 2026 demonstrates strong liquidity, allowing the company to sustain high dividend payouts and fund reinvestment.
The stock is viewed as a top-tier 'Dividend King' by hedge funds, offering consistency and reliability for long-term investors prioritizing stability over high yield.
Risk Factors
The stock trades at a forward P/E of approximately 21x, representing a substantial premium valuation that leaves little room for error if earnings growth slows.
The current dividend yield of roughly 2.5% is considered conservative and may not meet the income needs of investors seeking high immediate returns compared to bonds.
High valuation multiples imply that a fall in stock price could wipe out gains, even if the underlying business continues to perform reasonably well.
Colgate-Palmolive (CL) is exploring the potential sale of its mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, for over $1 billion. This strategic review aims to streamline the portfolio, reduce debt, and sharpen focus on higher-growth segments like Hill's Pet Nutrition and international markets, aligning with broader consumer staples rationalization trends.
The company reported robust cash generation in Q2 2026, delivering $1,742 million in operating cash flow for the first six months. Proceeds from divestitures would provide significant liquidity to pay down debt and optimize capital structure. However, shedding mature brands risks diminishing overall revenue scale and short-term earnings predictability, as these assets currently drive reliable volume.
In Q2 2026, Colgate posted net sales rising 4.9% to $5,361 million with organic sales up 2.4%. While gross margins expanded 140 basis points to 61.5%, divesting cash-generative brands could create near-term stranded overhead costs or margin dilution if restructuring is not executed cleanly. The move increases dependence on oral care and pet nutrition during market volatility, though emerging markets showed strong growth with a 13.7% net sales jump.
๐ CL considers selling mass-market brands for over $1B to reduce debt.
๐ฐ CL generated $1,742M operating cash flow in first six months of Q2 2026.
๐ Hill's Pet Nutrition drove growth with $1.18B net sales and 22% of total Q2 sales.
๐ Latin America showed strong performance with 13.7% Q2 net sales jump and 5.3% organic growth.
โ ๏ธ Divesting staples risks diminishing revenue scale and increasing vulnerability to channel headwinds.
๐ Colgate-Palmolive is considering selling mass-market personal care brands like Softsoap and Speed Stick for over $1 billion to reduce debt and focus on higher-growth engines.
๐ฐ The company generated $1,742 million in operating cash flow during the first six months of Q2 2026, providing liquidity for potential deleveraging.
๐ Hill's Pet Nutrition remains a key growth driver, generating $1.18 billion in net sales and representing 22% of total Q2 sales.
๐ International regions, particularly Latin America, demonstrated strong performance with Q2 net sales jumping 13.7% and organic growth of 5.3%.
โ ๏ธ Divesting established staples risks diminishing overall revenue scale and increasing vulnerability to channel headwinds in the broader business.
๐ North America faces volume pressures with a 3.9% decline, while lower private-label pet food sales contributed a 0.4% drag on organic growth.
๐ Gross margins expanded 140 basis points to 61.5% in Q2, though divestitures could create stranded overhead costs or margin dilution if restructuring is not clean.
๐ก๏ธ The strategic shift increases dependence on oral care and pet nutrition segments during periods of ongoing market volatility.
๐ Emerging markets offer stronger structural top-line expansion compared to mature North American mass personal care categories.
Bullish Signals
Exploring sale of non-core brands for over $1 billion to strengthen capital allocation.
Delivered robust cash generation with $1,742 million operating cash flow in first six months Q2 2026.
Hill's Pet Nutrition generated $1.18 billion net sales, accounting for 22% of total Q2 sales.
Latin America showed exceptional strength with Q2 net sales jumping 13.7% and organic growth of 5.3%.
Emerging markets and premium health brands offer stronger structural top-line expansion opportunities than mature North American mass personal care.
Risk Factors
Divesting staples risks revenue scale and earnings predictability.
North America volume declined 3.9% with pet food drag.
Cash-generative sales exit may cause margin dilution.
Bullish Signals
Colgate-Palmolive is exploring the sale of non-core brands for over $1 billion, which would directly strengthen its capital allocation strategy and deleveraging profile.
The company delivered robust cash generation with $1,742 million in operating cash flow for the first six months of Q2 2026.
Hill's Pet Nutrition is a high-performing growth engine that generated $1.18 billion in net sales, accounting for 22% of total Q2 sales.
International regions like Latin America showed exceptional strength with Q2 net sales jumping 13.7% and organic growth of 5.3%.
Emerging markets and premium health brands offer far stronger structural top-line expansion opportunities than mature North American mass personal care.
Risk Factors
Divesting established consumer staples like Softsoap and Speed Stick risks diminishing overall revenue scale and short-term earnings predictability.
The company faces volume pressures in select areas, including a 3.9% volume decline in North America and a 0.4% drag from lower private-label pet food sales.
Selling off reliable mass-market volume drivers leaves the broader business more vulnerable to channel headwinds and category concentration risks.
Divesting cash-generative brands could create near-term stranded overhead costs or margin dilution if restructuring is not executed cleanly.
Colgate-Palmolive reported second-quarter 2026 results with net sales of USD 5.361 billion, representing a 4.9% year-over-year increase. GAAP earnings per share declined 5% to USD 0.86, while Base Business EPS rose 8% to USD 0.99. The company achieved a gross margin of 61.5%, reflecting a significant 140-basis-point improvement driven by operational efficiency and pricing strategies.
Management highlighted strong contributions from emerging markets and Hill's Pet Nutrition as key growth drivers during the quarter. However, the North American business faced headwinds including retailer inventory reductions, market-share pressure, and softer demand for premium oral-care products. Consequently, management described second-half growth expectations as more volume-driven and raised full-year gross-margin guidance to remain flat.
Following the earnings release, Colgate-Palmolive stock traded at USD 86.06 on September 25, 2026, standing 13.27% below its 52-week high. Analyst sentiment remains mixed; Piper Sandler cut its price target to USD 95 while maintaining an Overweight rating, whereas the broader analyst consensus average target sits at USD 98.94. The market debate centers on whether international expansion and margin execution can sufficiently offset the weaker performance in North America.
Colgate-Palmolive maintains a long history of uninterrupted common-stock dividends since 1895, with a quarterly dividend of USD 0.53 declared for shareholders of record on October 20, 2026. With a market capitalization of USD 68.9 billion, the stock trades within its 52-week range of USD 74.55 to USD 99.33, offering investors exposure to a defensive consumer staple with improving margins but mixed regional outlooks.
๐ Q2 net sales rose 4.9% to USD 5.361 billion.
๐ฐ Base Business EPS grew 8% to USD 0.99.
๐ Emerging markets and Hill's Pet drove growth.
๐บ๐ธ North America faced headwinds from inventory cuts.
๐ Analysts raised full-year gross-margin guidance to flat.
๐ Colgate-Palmolive reported Q2 net sales of USD 5.361 billion, up 4.9% year over year.
๐ฐ GAAP EPS declined 5% to USD 0.86, while Base Business EPS increased 8% to USD 0.99.
๐ Gross margin improved by 140 basis points to reach 61.5% in the second quarter.
๐ Emerging markets and Hill's Pet Nutrition served as primary growth contributors for the quarter.
๐บ๐ธ North American business faced headwinds from retailer inventory reductions and softer premium oral-care demand.
Colgate-Palmolive has maintained a continuous dividend payment streak since 1895, recently extending its annual increase run to 63 years. The company retains strong dividend coverage and holds a global leadership position within the consumer goods sector.
Despite these defensive strengths, the firm faces significant headwinds as its North American business continues to shrink, creating distinct growth challenges for the long-term trajectory. This regional decline contrasts with the safety provided by its current high dividend yield of 2.46% and a market capitalization of $68.60 billion.
The stock currently trades at a premium valuation with a forward P/E ratio of 21, reflecting high market expectations that may not be fully supported by organic growth prospects. Management has provided mid-single-digit EPS growth guidance, but the current pricing leaves little room for error if North American operations fail to stabilize or improve.
Investors are closely monitoring whether the company can reverse its domestic decline to justify the expensive multiple. The market is balancing the appeal of a safe dividend yield against the risk that organic growth improvements in North America may be insufficient to sustain current valuations.
๐ Colgate-Palmolive extends annual dividend streak to 63 years since 1895.
๐ North American business shrinking threatens future organic growth targets.
๐ฐ Stock trades at premium forward P/E of 21 with $68.6B market cap.
Colgate-Palmolive shares declined 1.24% to $85.97 on September 23, 2026, trading 13.46% below its 52-week high of $99.33. The company reported second-quarter net sales of $5.36 billion, representing a 4.9% increase from the prior-year quarter, with organic sales growth of 2.4% indicating top-line expansion driven by volume rather than currency fluctuations.
Financial performance showed a divergence between adjusted and GAAP metrics. Base Business EPS rose 8% to $0.99, while GAAP EPS fell 5% to $0.86 due to non-operating items. Gross profit margins expanded significantly by 140 basis points to reach 61.5%, highlighting improved operational efficiency despite the broader market context.
Analyst sentiment remains cautious regarding cost headwinds. Piper Sandler lowered its price target from $98 to $95, citing rising oil costs as a potential pressure point for the first half of 2027 and noting pressured momentum in the US consumer goods category. The company maintains a quarterly cash dividend of $0.53 per share.
Market data indicates a market capitalization of approximately $68.8 billion. While sales growth is solid, the stock price pressure reflects investor concerns about input cost inflation and valuation adjustments by major financial institutions as they reassess the company's near-term profitability trajectory.
๐ CL stock fell 1.24% to $85.97 on Sept 23, 2026.
๐ฐ Q2 net sales rose 4.9% to $5.36 billion.
๐ Base EPS grew 8% to $0.99 while GAAP EPS dropped 5%.
๐ Gross profit margin expanded 140 bps to 61.5%.
โ ๏ธ Piper Sandler cut CL price target to $95 due to oil costs.
๐ Colgate-Palmolive stock fell 1.24% to $85.97 on September 23, 2026, trading 13.46% below its 52-week high.
๐ฐ Q2 net sales reached $5.36 billion, a 4.9% increase from the prior year with 2.4% organic growth.
๐ Base Business EPS increased 8% to $0.99 while GAAP EPS decreased 5% to $0.86 in Q2 2026.
๐ Gross profit margin expanded by 140 basis points to reach 61.5%, reflecting improved operational efficiency.
โ ๏ธ Piper Sandler cut its price target from $98 to $95, citing higher oil costs as a risk for H1 2027.
๐ต The company declared a quarterly cash dividend of $0.53 per share payable on November 13, 2026.
๐ข Colgate-Palmolive has a market capitalization of approximately $68.8 billion as of September 23, 2026.
Bullish Signals
Q2 net sales rose 4.9% to $5.36 billion.
Risk Factors
Piper Sandler cut target to $95 citing cost risks.
Rising oil costs may pressure margins in H1 2027.
US category momentum is pressured with softer demand.
Stock trades 13.46% below 52-week high.
Bullish Signals
Colgate-Palmolive reported Q2 net sales of $5.36 billion, marking a 4.9% increase from the prior-year quarter.
The company achieved organic sales growth of 2.4%, demonstrating that top-line expansion was driven by volume rather than currency effects.
Gross profit margin expanded significantly by 140 basis points to reach 61.5%, indicating strong operational efficiency.
Base Business EPS increased 8% to $0.99, showing robust underlying profitability before non-operating items.
Risk Factors
Piper Sandler analyst cut the price target from $98 to $95, reflecting concerns over cost risks and valuation pressure.
Rising oil costs are identified as a potential headwind that could pressure margins in the first half of 2027.
US category momentum is currently described as pressured, suggesting softer demand conditions in key markets.
The stock trades 13.46% below its 52-week high, indicating ongoing investor skepticism regarding near-term growth sustainability.
Colgate-Palmolive shares closed at USD 87.47 on the New York Stock Exchange on September 21, 2026, following a downgrade by analyst firm Piper Sandler. The company reported first-quarter 2026 results that exceeded market expectations, with revenue reaching USD 5.32 billion against a consensus estimate of USD 5.22 billion.
Despite the strong operational performance in Q1, Piper Sandler reduced its price target for Colgate-Palmolive from USD 98 to USD 95. The analyst firm cited soft consumer demand and intensified competition within the North American market as primary drivers for this revision, highlighting specific headwinds facing the consumer staples giant.
The earnings report showed the company delivered USD 0.97 per share in earnings, surpassing the consensus of USD 0.94. However, Piper Sandler maintained its 2026 EPS estimate at USD 3.85 while lowering its 2027 forecast to USD 4.12 from USD 4.23, reflecting concerns about future growth visibility despite current quarterly success.
Colgate-Palmolive's market capitalization was valued near USD 69.99 billion as of the reporting date. The stock traded approximately 11.9 percent below its 52-week high of USD 99.33, illustrating investor caution regarding the cited demand pressures and competitive landscape in key markets.
Colgate-Palmolive shares traded within a wide 52-week range between $74.54 and $99.33 as of September 18, 2026, reflecting investor focus on recent quarterly performance rather than immediate price volatility. The company's stock has experienced significant swings over the past year, with the current trading level positioned to allow for both downside protection and upside potential relative to historical extremes.
Fundamental analysis highlights mid-single-digit organic sales growth and expanding profit margins in the most recent quarter, demonstrating effective operating leverage and cost discipline. Net sales increased at a low-to-mid single-digit pace compared to the prior-year quarter, while earnings per share grew at a faster rate, indicating improved profitability trends that have persisted into the current fiscal year.
Analyst commentary from early September 2026 presents a mixed outlook, with some firms emphasizing the defensive nature of Colgate-Palmolive's consumer products portfolio while others prioritize valuation considerations. The company is preparing for its next quarterly earnings release, which will serve as a critical checkpoint to determine if recent sales growth and margin expansion can be sustained in future reporting cycles.
Market data indicates that the stock enters the new trading week with clear visibility into downside risk and upside potential relative to its recent earnings trajectory. The reported 12-month low of $74.54 and high of $99.33 provide a framework for investors to gauge the company's valuation status as it navigates the consumer staples sector.
๐ CL stock traded between USD 74.54 low and USD 99.33 high as of Sept 18, 2026.
๐ CL reported mid-single-digit organic sales growth and rising profits in recent quarterly results.
๐ฐ CL EPS grew faster than net sales, reflecting strong operating leverage and cost discipline.
๐๏ธ CL will release next quarterly earnings soon to assess sustainability of growth trends.
๐ Colgate-Palmolive stock traded between its 12-month low of USD 74.54 and high of USD 99.33 as of September 18, 2026.
๐ Recent quarterly results showed mid-single-digit organic sales growth and rising profits for the company.
๐ฐ Earnings per share increased at a faster pace than net sales, reflecting strong operating leverage and cost discipline.
๐ Analyst perspectives are mixed, with some emphasizing the defensive nature of the portfolio while others focus on valuation.
๐๏ธ The next quarterly earnings release is scheduled within the coming reporting cycle to assess sustainability of growth trends.
๐ญ The company operates in the Consumer Staples sector, specifically within Household and Personal Products.
Bullish Signals
Organic sales grew mid-single-digits.
Profits rose with expanding margins.
Net income and sales beat prior year.
EPS growth outpaced net sales.
Risk Factors
Analysts cite valuation concerns for the stock.
Stock trades near 12-month lows with downside risk.
Bullish Signals
Colgate-Palmolive reported mid-single-digit organic sales growth in its most recent quarter, demonstrating resilience in consumer demand.
The company achieved rising profits with expanding margins, translating into higher earnings per share compared to the same period a year earlier.
Net income and net sales were both higher than in the preceding fiscal year, underscoring a trend of improving profitability.
Earnings per share increased at a faster pace than net sales, highlighting effective operating leverage and cost management.
Risk Factors
Analyst commentary indicates mixed ratings on the stock, with some houses emphasizing valuation concerns as a key consideration.
The stock is positioned between its 12-month extremes, suggesting investors are weighing both downside risk and upside potential cautiously.
As of September 19, 2026, Colgate-Palmolive (CL) is trading at $87.47, which aligns with CleaRank Financial AI's fair value but falls below the Wall Street consensus target of $100.50 set by 21 analysts. Technical indicators suggest a bearish short-term outlook, with the stock trading below its 50-day average of $90.86 and 200-day moving average of $88.08, accompanied by negative MACD momentum.
Despite recent quarters where Colgate-Palmolive beat EPS estimates, the stock price has continued to decline, indicating that current earnings performance is not acting as a catalyst for upward price movement. Technical analysis highlights an RSI of 29.13, placing the stock in oversold territory which could precede a short-term technical bounce or reversal.
Insider trading data reveals a significant lack of confidence from management, with insiders having sold over $57.3 million worth of CL stock and no reported purchases. Long-term simulations project a base case price near $104 by 2030, representing a 1.2x increase from current levels, while downside scenarios could see the price drop to approximately $62.12.
๐ CL trades below Wall Street consensus target of $100.50.
๐ Technical indicators show bearish short-term outlook with negative momentum.
๐ฐ Insiders sold over $57.3 million in CL stock recently.
๐ฎ Monte Carlo simulations project CL base case price of $104 by 2030.
๐ CL trades at $87.47, aligning with CleaRank's fair value but remaining below the Wall Street consensus target of $100.50.
๐ Technical indicators show a bearish short-term outlook as the stock sits below its 50-day and 200-day moving averages with negative MACD momentum.
๐ฐ Insiders have sold over $57.3 million in CL stock with no reported purchases, signaling potential management lack of confidence.
๐ Recent quarters saw CL beat EPS estimates, yet the stock price declined, suggesting earnings are not currently driving valuation.
๐ฏ The RSI is at 29.13, indicating oversold conditions that could trigger a short-term technical bounce or reversal.
๐ฎ Monte Carlo simulations project a base case price of $104 for CL by 2030, assuming no dividend reinvestment.
Bullish Signals
Beat EPS estimates recently.
RSI at 29.13 shows oversold conditions.
Risk Factors
Insiders sold $57.3M stock with no purchases.
Stock trades below 50-day and 200-day averages.
Negative MACD signals bearish short-term outlook.
Bullish Signals
Colgate-Palmolive has beaten EPS estimates in recent quarters, demonstrating operational profitability despite stock price weakness.
The Relative Strength Index (RSI) is at 29.13, indicating oversold conditions that historically could precede a short-term technical bounce or reversal.
Risk Factors
Insiders have sold over $57.3 million worth of CL stock with no reported purchases, indicating a significant lack of confidence from management.
The stock is trading below its 50-day average of $90.86 and 200-day moving average of $88.08, suggesting continued potential for price declines.
Negative MACD momentum indicates a bearish short-term technical outlook for the company.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)